Discover and read the best of Twitter Threads about #Sézary
Most recents (2)
1/As promised & after reading $CRSP latest Q4 2022 #financial #report here is my impression regarding @CRISPRTX latest corporate status. I have focused only on the main issues that I found to be the most interesting & relevant. #CRISPR #BioTech #FinTwit #Genomics #GeneEditing 🧵 
2/IMO the most significant corporate event in Q4 was $CRSP announcement that regulatory Exa-cel submissions of both #SickleCell & #BetaThalassemia validated in the #EU & #UK & that the @US_FDA BLA submission is on track by the end of Q1 ‘23 - possibly reaching the #markets in ‘23
3/Exa-cel/CTX001 - the key program in $CRSP portfolio, is an #autologous Ex-Vivo #CRISPR/#Cas9 #GeneEditing therapy aimed for patients suffering from #TDT or severe #SCD. The latest readout for both programs was phenomenal with 42/44 TDT & 31/31(!) demonstrated remarkable results
It's overdue. Time for a #dermtwitter #tweetorial on...
SEZARY SYNDROME!
We're going to focus on presentation and work up!
#sezary #ctcl #medtwitter #onctwitter #meded #FOAMEd
1/
SEZARY SYNDROME!
We're going to focus on presentation and work up!
#sezary #ctcl #medtwitter #onctwitter #meded #FOAMEd
1/
Just a few years ago, Sezary Syndrome (SS) was thought to be the leukemic variant of Mycosis Fungoides (MF). We basically thought people had MF, it would keep getting worse, and then it would turn into SS.
Check out my old #tweetorial on MF here👇
2/
Check out my old #tweetorial on MF here👇
2/
But patients often present with either the classic SS exam (red all over, super itchy), or with MF. Some patients would progress from MF--> SS, but it's the minority. So it became clear these are two different processes.
For that reason, we've changed how we think about it...
3/
For that reason, we've changed how we think about it...
3/
